1 / 10

G-Zero Therapeutics

G-Zero Therapeutics. Contact: John Chant, 650-307-7770; chant_john@hotmail.com. 100. Minus 4 hrs (N=22). Percent Survival. 50. Untreated (N=28). 0. 0. 10. 20. 30. 40. Days after 7.5 Gy TBI. Protection BEFORE Treatment.

africa
Download Presentation

G-Zero Therapeutics

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. G-Zero Therapeutics Contact: John Chant, 650-307-7770; chant_john@hotmail.com

  2. 100 Minus 4 hrs (N=22) Percent Survival 50 Untreated (N=28) 0 0 10 20 30 40 Days after 7.5 Gy TBI Protection BEFORE Treatment Models Radioprotection and Chemoprotection Clinical Oncology Supportive Care

  3. Treating Bone Marrow Suppression Stem Cell G-Zero: PharmacoQuiescence™ (PQ™) Multi-potent Progenitors Common Lymphoid Progenitor Common Myeloid Progenitor Megakaryocyte-Erythroid Prog. Granulocyte-Monocyte Prog. Erythrocytes Platelets Granulocytes Macrophages T-cells B-cells EPO® Neupogen® Unmet* Unmet 4.3B 4.6B *Neumega ® (Wyeth)—very minor product

  4. All Lineages Protected Nadir blood counts 21 days after 7.5 Gy of TBI 60 600 4.0 2.0 0.8 45 450 3.0 1.5 0.5 Percent 103 / uL 103 / uL 103 / uL 103 / uL 30 300 2.0 1.0 0.3 15 150 1.0 0.5 # # Total White Blood Count Hematocrit Platelets Lymphocytes Myeloid Cells Untreated (n=4) Treated (n=5) 9

  5. Proprietary small molecule therapeutics that prevent bone marrow suppression Novel method: no other small molecule does this Intellectual property from Sharpless Lab Technology

  6. Applications • Protect bone marrow during chemotherapy for cancer • $5B+ market per year • Government sponsored market: radiation mitigation • $200-250M contracts available so stockpile • Generous non-dilutive financing: SBIR, etc. G-Zero Technology is Demonstrably Superior to Existing Treatments

  7. Research operations housed in Lineberger Comprehensive Cancer Center Subcontractors/Consultants in place Non-dilutive financing in place Current Status

  8. Founders Norman “Ned” Sharpless , MD Clinical Oncologist UNC Medical School, Lineberger Comprehensive Cancer Center Kwok-kin Wong, MD Ph D Clinical Oncologist Dana Farber Cancer Institute, Harvard Medical School John Chant Ph D President, G-Zero Therapeutics Former: Harvard University, CuraGen/454, Genentech Oncology

  9. Needs • To achieve proof of concept trial in humans for chemoprotection and approval for radioprotection $5M/2-3 years ** • To achieve NDA for chemoprotection $10M additional/additional 1-2 years ** **budget numbers do not account for government funding

  10. G-Zero Therapeutics Contact: John Chant, 650-307-7770; chant_john@hotmail.com

More Related